XOMA Corporation (XOMA)
USD 18.78
(-3.4%)
USD 18.78
(-3.4%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.86 Million USD | -34.94% |
| 2022 | 5.93 Million USD | -84.39% |
| 2021 | 37.98 Million USD | 30.03% |
| 2020 | 29.21 Million USD | 70.68% |
| 2019 | 17.11 Million USD | 373.24% |
| 2018 | 3.61 Million USD | -91.93% |
| 2017 | 44.81 Million USD | 976.25% |
| 2016 | 4.16 Million USD | -88.02% |
| 2015 | 34.74 Million USD | 427.77% |
| 2014 | -10.6 Million USD | -231.05% |
| 2013 | 8.08 Million USD | -75.95% |
| 2012 | 33.63 Million USD | -42.2% |
| 2011 | 58.19 Million USD | 72.99% |
| 2010 | 33.64 Million USD | -65.82% |
| 2009 | 98.43 Million USD | 44.78% |
| 2008 | 67.98 Million USD | -19.31% |
| 2007 | 84.25 Million USD | 185.62% |
| 2006 | 29.49 Million USD | 58.01% |
| 2005 | 18.66 Million USD | 246.91% |
| 2004 | -12.7 Million USD | -152.06% |
| 2003 | 24.41 Million USD | -18.49% |
| 2002 | 29.94 Million USD | 73.33% |
| 2001 | 17.27 Million USD | 260.73% |
| 2000 | 4.79 Million USD | 33.06% |
| 1999 | 3.6 Million USD | -54.43% |
| 1998 | 7.9 Million USD | -61.27% |
| 1997 | 20.4 Million USD | 257.89% |
| 1996 | 5.7 Million USD | 39.02% |
| 1995 | 4.1 Million USD | -18.0% |
| 1994 | 5 Million USD | 56.25% |
| 1993 | 3.2 Million USD | -45.76% |
| 1992 | 5.9 Million USD | -44.34% |
| 1991 | 10.6 Million USD | -28.86% |
| 1990 | 14.9 Million USD | 207.97% |
| 1989 | -13.8 Million USD | -45.26% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.48 Million USD | -7.46% |
| 2024 Q2 | 11.08 Million USD | 644.83% |
| 2023 FY | 3.85 Million USD | -34.94% |
| 2023 Q1 | 212 Thousand USD | -84.74% |
| 2023 Q3 | 606 Thousand USD | -57.74% |
| 2023 Q4 | 1.6 Million USD | 165.35% |
| 2023 Q2 | 1.43 Million USD | 576.42% |
| 2022 Q3 | 404 Thousand USD | -57.16% |
| 2022 Q1 | 3.06 Million USD | -91.47% |
| 2022 Q2 | 943 Thousand USD | -69.21% |
| 2022 FY | 5.93 Million USD | -84.39% |
| 2022 Q4 | 1.38 Million USD | 243.81% |
| 2021 Q2 | 863 Thousand USD | 174.84% |
| 2021 Q1 | 314 Thousand USD | -98.86% |
| 2021 FY | 37.98 Million USD | 30.03% |
| 2021 Q4 | 35.9 Million USD | 3845.27% |
| 2021 Q3 | 910 Thousand USD | 5.45% |
| 2020 Q2 | 406 Thousand USD | -45.28% |
| 2020 Q1 | 742 Thousand USD | 153.24% |
| 2020 FY | 29.21 Million USD | 70.68% |
| 2020 Q3 | 523 Thousand USD | 28.82% |
| 2020 Q4 | 27.54 Million USD | 5166.54% |
| 2019 Q4 | 293 Thousand USD | -96.64% |
| 2019 FY | 17.11 Million USD | 373.24% |
| 2019 Q1 | 7.87 Million USD | 443.85% |
| 2019 Q2 | 238 Thousand USD | -96.98% |
| 2019 Q3 | 8.71 Million USD | 3560.5% |
| 2018 Q1 | 31 Thousand USD | -99.34% |
| 2018 Q2 | 1.87 Million USD | 5961.29% |
| 2018 Q3 | 259 Thousand USD | -86.22% |
| 2018 Q4 | 1.44 Million USD | 459.07% |
| 2018 FY | 3.61 Million USD | -91.93% |
| 2017 Q2 | 8.67 Million USD | 332.39% |
| 2017 Q1 | -3.73 Million USD | 89.04% |
| 2017 FY | 44.81 Million USD | 976.25% |
| 2017 Q4 | 4.69 Million USD | -86.65% |
| 2017 Q3 | 35.17 Million USD | 305.49% |
| 2016 Q1 | -9.64 Million USD | -121.33% |
| 2016 FY | 4.16 Million USD | -88.02% |
| 2016 Q4 | -34.06 Million USD | -323.71% |
| 2016 Q3 | -8.03 Million USD | 39.37% |
| 2016 Q2 | -13.26 Million USD | -37.44% |
| 2015 FY | 34.74 Million USD | 427.77% |
| 2015 Q1 | -3.68 Million USD | -53.77% |
| 2015 Q3 | -3.49 Million USD | -7.55% |
| 2015 Q2 | -3.24 Million USD | 11.98% |
| 2015 Q4 | 45.22 Million USD | 1395.22% |
| 2014 Q2 | -2.51 Million USD | 20.65% |
| 2014 FY | -10.6 Million USD | -231.05% |
| 2014 Q1 | -3.16 Million USD | -125.4% |
| 2014 Q3 | -2.52 Million USD | -0.32% |
| 2014 Q4 | -2.39 Million USD | 4.84% |
| 2013 Q1 | 9.4 Million USD | 27.83% |
| 2013 Q2 | 7.13 Million USD | -24.21% |
| 2013 FY | 8.08 Million USD | -75.95% |
| 2013 Q3 | -11.88 Million USD | -266.7% |
| 2013 Q4 | 12.46 Million USD | 204.89% |
| 2012 Q2 | 9.19 Million USD | -6.8% |
| 2012 FY | 33.63 Million USD | -42.2% |
| 2012 Q4 | 7.35 Million USD | 1.88% |
| 2012 Q3 | 7.22 Million USD | -21.44% |
| 2012 Q1 | 9.86 Million USD | 0.18% |
| 2011 Q1 | 15.59 Million USD | 62.45% |
| 2011 Q2 | 16.52 Million USD | 5.96% |
| 2011 Q3 | 16.22 Million USD | -1.79% |
| 2011 Q4 | 9.84 Million USD | -39.32% |
| 2011 FY | 58.19 Million USD | 72.99% |
| 2010 Q3 | 10.89 Million USD | 83.39% |
| 2010 FY | 33.64 Million USD | -65.82% |
| 2010 Q1 | 7.2 Million USD | -66.65% |
| 2010 Q4 | 9.6 Million USD | -11.9% |
| 2010 Q2 | 5.94 Million USD | -17.5% |
| 2009 Q4 | 21.59 Million USD | -21.24% |
| 2009 Q3 | 27.42 Million USD | 182.54% |
| 2009 FY | 98.43 Million USD | 44.78% |
| 2009 Q2 | 9.7 Million USD | -75.55% |
| 2009 Q1 | 39.7 Million USD | 7.54% |
| 2008 FY | 67.98 Million USD | -19.31% |
| 2008 Q4 | 36.92 Million USD | 367.7% |
| 2008 Q3 | 7.89 Million USD | -28.99% |
| 2008 Q2 | 11.11 Million USD | -7.8% |
| 2008 Q1 | 12.05 Million USD | -18.11% |
| 2007 FY | 84.25 Million USD | 185.62% |
| 2007 Q4 | 14.72 Million USD | -65.87% |
| 2007 Q3 | 43.14 Million USD | 205.18% |
| 2007 Q2 | 14.13 Million USD | 15.38% |
| 2007 Q1 | 12.25 Million USD | 35.73% |
| 2006 Q1 | 5.6 Million USD | -8.0% |
| 2006 FY | 29.49 Million USD | 58.01% |
| 2006 Q4 | 9.02 Million USD | 22.73% |
| 2006 Q3 | 7.35 Million USD | -2.09% |
| 2006 Q2 | 7.51 Million USD | 34.05% |
| 2005 Q3 | 4.42 Million USD | -14.21% |
| 2005 Q2 | 5.15 Million USD | 72.37% |
| 2005 FY | 18.66 Million USD | 246.91% |
| 2005 Q1 | 2.99 Million USD | 121.06% |
| 2005 Q4 | 6.09 Million USD | 37.62% |
| 2004 Q3 | -3.29 Million USD | 25.27% |
| 2004 Q1 | -3.06 Million USD | -149.05% |
| 2004 FY | -12.7 Million USD | -152.06% |
| 2004 Q4 | -14.21 Million USD | -331.02% |
| 2004 Q2 | -4.41 Million USD | -43.84% |
| 2003 Q2 | 2.36 Million USD | -25.38% |
| 2003 Q1 | 3.16 Million USD | -73.12% |
| 2003 Q4 | 6.25 Million USD | -50.48% |
| 2003 Q3 | 12.63 Million USD | 435.03% |
| 2003 FY | 24.41 Million USD | -18.49% |
| 2002 Q2 | 4.72 Million USD | -48.77% |
| 2002 Q4 | 11.77 Million USD | 178.05% |
| 2002 Q1 | 9.22 Million USD | 55.62% |
| 2002 FY | 29.94 Million USD | 73.33% |
| 2002 Q3 | 4.23 Million USD | -10.39% |
| 2001 Q2 | 5.21 Million USD | 82.49% |
| 2001 Q4 | 5.92 Million USD | 80.4% |
| 2001 FY | 17.27 Million USD | 260.73% |
| 2001 Q1 | 2.85 Million USD | 199.69% |
| 2001 Q3 | 3.28 Million USD | -36.97% |
| 2000 Q4 | 953 Thousand USD | 11.99% |
| 2000 FY | 4.79 Million USD | 33.06% |
| 2000 Q3 | 851 Thousand USD | -62.72% |
| 2000 Q2 | 2.28 Million USD | -11.24% |
| 2000 Q1 | 2.57 Million USD | 42.89% |
| 1999 Q4 | 1.8 Million USD | 1700.0% |
| 1999 Q3 | 100 Thousand USD | -80.0% |
| 1999 FY | 3.6 Million USD | -54.43% |
| 1999 Q2 | 500 Thousand USD | 400.0% |
| 1999 Q1 | 100 Thousand USD | -98.18% |
| 1998 Q4 | 5.5 Million USD | 587.5% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 FY | 7.9 Million USD | -61.27% |
| 1998 Q1 | 100 Thousand USD | -99.42% |
| 1998 Q3 | 800 Thousand USD | 700.0% |
| 1997 Q4 | 17.3 Million USD | 17200.0% |
| 1997 Q3 | 100 Thousand USD | -66.67% |
| 1997 Q2 | 300 Thousand USD | -57.14% |
| 1997 Q1 | 700 Thousand USD | 0.0% |
| 1997 FY | 20.4 Million USD | 257.89% |
| 1996 FY | 5.7 Million USD | 39.02% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q3 | 500 Thousand USD | -83.33% |
| 1996 Q4 | - USD | -100.0% |
| 1996 Q2 | 3 Million USD | 2900.0% |
| 1995 Q1 | 1.1 Million USD | 0.0% |
| 1995 FY | 4.1 Million USD | -18.0% |
| 1995 Q4 | 100 Thousand USD | 0.0% |
| 1995 Q3 | 100 Thousand USD | 0.0% |
| 1995 Q2 | 100 Thousand USD | -90.91% |
| 1994 Q3 | 100 Thousand USD | -92.86% |
| 1994 FY | 5 Million USD | 56.25% |
| 1994 Q4 | - USD | -100.0% |
| 1994 Q2 | 1.4 Million USD | 600.0% |
| 1994 Q1 | 200 Thousand USD | -92.86% |
| 1993 Q1 | 200 Thousand USD | -93.55% |
| 1993 Q4 | 2.8 Million USD | 2700.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q2 | - USD | -100.0% |
| 1993 FY | 3.2 Million USD | -45.76% |
| 1992 Q4 | 3.1 Million USD | 1133.33% |
| 1992 FY | 5.9 Million USD | -44.34% |
| 1992 Q1 | 1.9 Million USD | -20.83% |
| 1992 Q2 | 1.2 Million USD | -36.84% |
| 1992 Q3 | -300 Thousand USD | -125.0% |
| 1991 Q2 | 2.7 Million USD | -15.63% |
| 1991 Q3 | 2.3 Million USD | -14.81% |
| 1991 Q4 | 2.4 Million USD | 4.35% |
| 1991 FY | 10.6 Million USD | -28.86% |
| 1991 Q1 | 3.2 Million USD | -27.27% |
| 1990 Q1 | 5.9 Million USD | 247.5% |
| 1990 Q3 | 2.5 Million USD | 19.05% |
| 1990 Q2 | 2.1 Million USD | -64.41% |
| 1990 FY | 14.9 Million USD | 207.97% |
| 1990 Q4 | 4.4 Million USD | 76.0% |
| 1989 FY | -13.8 Million USD | -45.26% |
| 1989 Q1 | 700 Thousand USD | -56.25% |
| 1989 Q3 | -3.2 Million USD | -3.23% |
| 1989 Q2 | -3.1 Million USD | -542.86% |
| 1989 Q4 | -4 Million USD | -25.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AbCellera Biologics Inc. | 38.02 Million USD | 89.846% |
| Alkermes plc | 1.37 Billion USD | 99.719% |
| Agenus Inc. | 139.61 Million USD | 97.235% |
| Aptorum Group Limited | -1.11 Million USD | 446.375% |
| Ardelyx, Inc. | 106.66 Million USD | 96.38% |
| Dyadic International, Inc. | 922.95 Thousand USD | -318.329% |
| Eton Pharmaceuticals, Inc. | 21.06 Million USD | 81.668% |
| Lantern Pharma Inc. | -174.84 Thousand USD | 2308.267% |
| Inhibikase Therapeutics, Inc. | -13.35 Million USD | 128.904% |
| Novavax, Inc. | 639.93 Million USD | 99.397% |
| Janux Therapeutics, Inc. | -46.83 Million USD | 108.243% |
| Pyxis Oncology, Inc. | -2 Million USD | 293.05% |
| TransCode Therapeutics, Inc. | -516.74 Thousand USD | 847.176% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | 79.725% |
| Outlook Therapeutics, Inc. | -44.18 Thousand USD | 8837.666% |
| Madrigal Pharmaceuticals, Inc. | -527 Thousand USD | 832.638% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| SELLAS Life Sciences Group, Inc. | - USD | -Infinity% |
| Syros Pharmaceuticals, Inc. | -98.21 Million USD | 103.931% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | -381.421% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 4808.537% |
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | 97.146% |
| Clearside Biomedical, Inc. | 7.87 Million USD | 50.947% |
| C4 Therapeutics, Inc. | -96.95 Million USD | 103.982% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 99.746% |
| AlloVir, Inc. | -398 Thousand USD | 1070.101% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 98.396% |
| VYNE Therapeutics Inc. | 424 Thousand USD | -810.613% |
| Bicycle Therapeutics plc | -129.52 Million USD | 102.981% |
| BioXcel Therapeutics, Inc. | 120 Thousand USD | -3117.5% |
| ChromaDex Corporation | 50.78 Million USD | 92.397% |
| Chimerix, Inc. | 324 Thousand USD | -1091.667% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 112.388% |
| Caribou Biosciences, Inc. | -77.59 Million USD | 104.976% |
| CRISPR Therapeutics AG | 240.95 Million USD | 98.398% |
| Precision BioSciences, Inc. | 40.47 Million USD | 90.46% |
| Fate Therapeutics, Inc. | -98.16 Million USD | 103.933% |
| Fortress Biotech, Inc. | 57.85 Million USD | 93.326% |
| Fortress Biotech, Inc. | 57.85 Million USD | 93.326% |
| HOOKIPA Pharma Inc. | 16.57 Million USD | 76.709% |
| ImmuCell Corporation | 4.39 Million USD | 12.176% |
| IDEAYA Biosciences, Inc. | -106.12 Million USD | 103.638% |
| Immix Biopharma, Inc. | -5468.00 USD | 70710.827% |
| Incyte Corporation | 3.44 Billion USD | 99.888% |
| Innoviva, Inc. | 261.06 Million USD | 98.521% |
| IO Biotech, Inc. | -756 Thousand USD | 610.714% |
| Jaguar Health, Inc. | 7.72 Million USD | 50.013% |
| Keros Therapeutics, Inc. | -664 Thousand USD | 681.476% |
| Ligand Pharmaceuticals Incorporated | 119.75 Million USD | 96.776% |
| ContextLogic Inc. | 59 Million USD | 93.456% |
| MiMedx Group, Inc. | 266.84 Million USD | 98.553% |
| MEI Pharma, Inc. | 49.32 Million USD | 92.173% |
| NextCure, Inc. | -3.68 Million USD | 204.805% |
| Onconetix, Inc. | -1.12 Million USD | 442.541% |
| Oncternal Therapeutics, Inc. | -28.96 Million USD | 113.329% |
| Opthea Limited | 21.72 Thousand USD | -17676.243% |
| Psyence Biomedical Ltd. | -240.00 USD | 1608850.0% |
| Vaxcyte, Inc. | -75 Million USD | 105.148% |
| PDS Biotechnology Corporation | -57.32 Thousand USD | 6835.164% |
| Precigen, Inc. | 106 Thousand USD | -3542.453% |
| Pharming Group N.V. | 220.1 Million USD | 98.246% |
| Phathom Pharmaceuticals, Inc. | 515 Thousand USD | -649.709% |
| Pieris Pharmaceuticals, Inc. | 1 Million USD | -282.656% |
| PureTech Health plc | -1.6 Million USD | 340.861% |
| Rigel Pharmaceuticals, Inc. | 109.77 Million USD | 96.483% |
| Avidity Biosciences, Inc. | -181.4 Million USD | 102.128% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 108.518% |
| Sol-Gel Technologies Ltd. | -21.98 Million USD | 117.56% |
| Acelyrin, Inc. | -115 Thousand USD | 3457.391% |
| Salarius Pharmaceuticals, Inc. | -10.05 Thousand USD | 38514.088% |
| Summit Therapeutics Inc. | -2.05 Million USD | 288.341% |
| Sensei Biotherapeutics, Inc. | -571 Thousand USD | 776.182% |
| Senti Biosciences, Inc. | -2.68 Million USD | 243.906% |
| Stoke Therapeutics, Inc. | 4.05 Million USD | 4.69% |
| Elevation Oncology, Inc. | -39 Thousand USD | 10000.0% |
| Alaunos Therapeutics, Inc. | -4.79 Million USD | 180.471% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 197.944% |
| Entrada Therapeutics, Inc. | 29.12 Million USD | 86.745% |
| VistaGen Therapeutics, Inc. | 496 Thousand USD | -678.427% |
| Kintara Therapeutics, Inc. | -55 Thousand USD | 7120.0% |
| Wave Life Sciences Ltd. | 104.09 Million USD | 96.291% |
| Seer, Inc. | 7.02 Million USD | 45.055% |
| Verrica Pharmaceuticals Inc. | 4.37 Million USD | 11.809% |
| Aadi Bioscience, Inc. | 21.54 Million USD | 82.079% |
| ESSA Pharma Inc. | -118.49 Thousand USD | 3358.475% |
| GlycoMimetics, Inc. | -143.3 Thousand USD | 2794.329% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Inhibrx Biosciences, Inc. | 609 Thousand USD | -533.99% |
| Akebia Therapeutics, Inc. | 120.47 Million USD | 96.795% |
| Catalyst Pharmaceuticals, Inc. | 313.67 Million USD | 98.769% |
| Longboard Pharmaceuticals, Inc. | -5000.00 USD | 77320.0% |
| Orchestra BioMed Holdings, Inc. | 2.57 Million USD | -50.0% |
| Alzamend Neuro, Inc. | -50.74 Thousand USD | 7709.381% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 86.862% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 1764.224% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 884.756% |
| Rocket Pharmaceuticals, Inc. | -7.09 Million USD | 154.396% |
| Aptose Biosciences Inc. | -474.54 Thousand USD | 913.621% |
| ZyVersa Therapeutics, Inc. | -10.4 Thousand USD | 37225.0% |
| Soligenix, Inc. | 97.31 Thousand USD | -3867.691% |
| Century Therapeutics, Inc. | -10.8 Million USD | 135.72% |
| Kura Oncology, Inc. | -849 Thousand USD | 554.77% |
| TScan Therapeutics, Inc. | -67.1 Million USD | 105.754% |
| Intensity Therapeutics, Inc. | -147 Thousand USD | 2726.531% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 99.03 Million USD | 96.102% |
| Autolus Therapeutics plc | -4.86 Million USD | 179.33% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 41.38 Million USD | 90.671% |
| Eterna Therapeutics Inc. | -168 Thousand USD | 2398.214% |
| Adaptive Biotechnologies Corporation | 94.72 Million USD | 95.924% |
| GRI Bio, Inc. | 10.84 Million USD | 64.385% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | -52.009% |
| Tenaya Therapeutics, Inc. | -8.68 Million USD | 144.446% |
| IGM Biosciences, Inc. | -211.66 Million USD | 101.824% |
| INmune Bio, Inc. | 155 Thousand USD | -2390.968% |
| Heron Therapeutics, Inc. | 61.93 Million USD | 93.766% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 356.325% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 695.416% |
| Entero Therapeutics, Inc. | -29.27 Thousand USD | 13289.178% |
| Milestone Pharmaceuticals Inc. | 402 Thousand USD | -860.448% |
| X4 Pharmaceuticals, Inc. | -1.99 Million USD | 293.437% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 1333.546% |
| Coherus BioSciences, Inc. | 94.46 Million USD | 95.913% |
| Verastem, Inc. | -62 Thousand USD | 6327.419% |
| Abeona Therapeutics Inc. | 2.43 Million USD | -58.563% |
| Pliant Therapeutics, Inc. | -261 Thousand USD | 1579.31% |
| Tonix Pharmaceuticals Holding Corp. | 3.02 Million USD | -27.552% |
| Histogen Inc. | 3.76 Million USD | -2.441% |
| Aprea Therapeutics, Inc. | 576.17 Thousand USD | -570.104% |
| Surrozen, Inc. | -27.23 Million USD | 114.179% |
| Organovo Holdings, Inc. | -5.38 Million USD | 171.646% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | -1.2 Million USD | 420.447% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 115.054% |
| CASI Pharmaceuticals, Inc. | 20.05 Million USD | 80.745% |
| Cadrenal Therapeutics, Inc. Common Stock | -1980.00 USD | 195100.0% |
| Centessa Pharmaceuticals plc | 6.06 Million USD | 36.355% |
| Hepion Pharmaceuticals, Inc. | -67.13 Thousand USD | 5851.441% |
| Arcturus Therapeutics Holdings Inc. | 154.79 Million USD | 97.506% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | -2548.148% |
| Apollomics, Inc. | 127 Thousand USD | -2940.157% |
| Amarin Corporation plc | 165.54 Million USD | 97.668% |
| Mesoblast Limited | -9.81 Million USD | 139.338% |
| Turnstone Biologics Corp. | 16.5 Million USD | 76.609% |
| Kymera Therapeutics, Inc. | -110.48 Million USD | 103.494% |
| Synaptogenix, Inc. | -6347.00 USD | 60931.889% |
| Tiziana Life Sciences Ltd | -51 Thousand USD | 7670.588% |
| Aurinia Pharmaceuticals Inc. | 161.36 Million USD | 97.607% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 1.75 Billion USD | 99.78% |
| Better Therapeutics, Inc. | -2.72 Million USD | 241.48% |
| Nurix Therapeutics, Inc. | -112.16 Million USD | 103.442% |
| Apellis Pharmaceuticals, Inc. | 338.08 Million USD | 98.858% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 33944.67% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | -6.26 Million USD | 161.677% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 448.466% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 7.31 Million USD | 47.24% |
| Insmed Incorporated | 239.63 Million USD | 98.389% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 3.57 Million USD | -7.909% |
| OmniAb, Inc. | 14.66 Million USD | 73.676% |
| Alector, Inc. | -95.05 Million USD | 104.062% |
| Seres Therapeutics, Inc. | 125.62 Million USD | 96.926% |
| Checkpoint Therapeutics, Inc. | -43.46 Million USD | 108.883% |
| Zai Lab Limited | 170.9 Million USD | 97.741% |
| Revance Therapeutics, Inc. | 81.87 Million USD | 95.284% |
| Aura Biosciences, Inc. | -1.29 Million USD | 398.147% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | -2870.0% |
| Immunic, Inc. | -111 Thousand USD | 3578.378% |
| Tarsus Pharmaceuticals, Inc. | 15.85 Million USD | 75.647% |
| Veracyte, Inc. | 248.14 Million USD | 98.444% |
| InMed Pharmaceuticals Inc. | -6.98 Billion USD | 100.055% |
| FibroGen, Inc. | 128.9 Million USD | 97.005% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| Adial Pharmaceuticals, Inc. | -564.00 USD | 684674.468% |
| Sonnet BioTherapeutics Holdings, Inc. | -11.66 Million USD | 133.094% |
| Jazz Pharmaceuticals plc | 3.39 Billion USD | 99.886% |
| Cyclacel Pharmaceuticals, Inc. | 389 Thousand USD | -892.545% |
| Amylyx Pharmaceuticals, Inc. | 355.34 Million USD | 98.913% |
| TG Therapeutics, Inc. | 219.1 Million USD | 98.238% |
| Galecto, Inc. | -830 Thousand USD | 565.181% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 378.773% |
| Fortrea Holdings Inc. | 424 Million USD | 99.089% |
| KalVista Pharmaceuticals, Inc. | -86.16 Million USD | 104.481% |
| Aptevo Therapeutics Inc. | -567 Thousand USD | 780.952% |
| XBiotech Inc. | -1.74 Million USD | 321.388% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 448.466% |
| Lyra Therapeutics, Inc. | -46.47 Million USD | 108.308% |
| Foghorn Therapeutics Inc. | -75.53 Million USD | 105.112% |
| Y-mAbs Therapeutics, Inc. | 73.4 Million USD | 94.74% |
| Theravance Biopharma, Inc. | 16.8 Million USD | 77.022% |
| Ultragenyx Pharmaceutical Inc. | 389.04 Million USD | 99.008% |
| Metagenomi, Inc. Common Stock | -49.64 Million USD | 107.777% |
| Vaxxinity, Inc. | -2.23 Million USD | 272.829% |
| BioCryst Pharmaceuticals, Inc. | 326.75 Million USD | 98.818% |
| Gain Therapeutics, Inc. | -11.32 Million USD | 134.096% |
| Cartesian Therapeutics, Inc. | 24.45 Million USD | 84.209% |
| NexImmune, Inc. | -1.02 Million USD | 476.693% |
| Creative Medical Technology Holdings, Inc. | 5400.00 USD | -71400.0% |
| Marker Therapeutics, Inc. | -7.1 Million USD | 154.337% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.966% |
| Chemomab Therapeutics Ltd. | -66.82 Thousand USD | 5877.605% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | -3.55 Million USD | 208.73% |
| Ainos, Inc. | -253.73 Thousand USD | 1621.678% |
| Pluri Inc. | 322 Thousand USD | -1099.068% |
| Prothena Corporation plc | -129.2 Million USD | 102.988% |
| Adaptimmune Therapeutics plc | 50.42 Million USD | 92.343% |
| Celularity Inc. | 6.75 Million USD | 42.842% |
| Rallybio Corporation | -150 Thousand USD | 2674.0% |
| Cue Biopharma, Inc. | -32.6 Million USD | 111.841% |
| MeiraGTx Holdings plc | 287 Thousand USD | -1245.296% |
| Omeros Corporation | -69.77 Million USD | 105.533% |
| Humacyte, Inc. | -76.55 Million USD | 105.044% |
| Immunocore Holdings plc | 248.39 Million USD | 98.446% |
| Cocrystal Pharma, Inc. | -15.16 Million USD | 125.453% |
| Cidara Therapeutics, Inc. | 62.38 Million USD | 93.811% |
| Blueprint Medicines Corporation | 236.58 Million USD | 98.368% |
| CalciMedica, Inc. | -58 Thousand USD | 6756.897% |
| Cabaletta Bio, Inc. | -1.42 Million USD | 370.757% |
| Marinus Pharmaceuticals, Inc. | 29.05 Million USD | 86.711% |
| Scholar Rock Holding Corporation | -2.84 Million USD | 235.759% |
| Sana Biotechnology, Inc. | -30.86 Million USD | 112.509% |
| Pulmatrix, Inc. | -8.22 Million USD | 146.971% |
| Elicio Therapeutics, Inc. | -1.17 Million USD | 430.0% |
| Vigil Neuroscience, Inc. | -399 Thousand USD | 1067.669% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 100.968% |
| Adlai Nortye Ltd. American Depositary Shares | 2.77 Million USD | -39.106% |
| Cytokinetics, Incorporated | -322.59 Million USD | 101.197% |
| Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | -347.857% |
| Protara Therapeutics, Inc. | -341 Thousand USD | 1232.258% |
| Vor Biopharma Inc. | -3.49 Million USD | 210.567% |
| Roivant Sciences Ltd. | 109.23 Million USD | 96.465% |
| Evogene Ltd. | 1.39 Million USD | -175.983% |
| ProKidney Corp. | -3.16 Million USD | 221.837% |
| Applied Therapeutics, Inc. | -43.91 Million USD | 108.793% |
| Hoth Therapeutics, Inc. | - USD | -Infinity% |
| BridgeBio Pharma, Inc. | 6.85 Million USD | 43.693% |
| CorMedix Inc. | -205.56 Thousand USD | 1978.265% |
| BioLineRx Ltd. | 1.1 Million USD | -248.466% |
| Tango Therapeutics, Inc. | -78.67 Million USD | 104.908% |
| Galectin Therapeutics Inc. | -33 Thousand USD | 11800.0% |
| Atai Life Sciences N.V. | -5000.00 USD | 77320.0% |
| Renovaro Biosciences Inc. | -121.85 Thousand USD | 3268.416% |
| Aerovate Therapeutics, Inc. | -96 Thousand USD | 4121.875% |
| Zentalis Pharmaceuticals, Inc. | -1.38 Million USD | 377.97% |
| Sagimet Biosciences Inc. | 2 Million USD | -93.05% |
| MediciNova, Inc. | 979.7 Thousand USD | -294.098% |
| Praxis Precision Medicines, Inc. | -84.31 Million USD | 104.579% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 4183.338% |
| GeoVax Labs, Inc. | -20.72 Million USD | 118.633% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 98.421% |
| Biomea Fusion, Inc. | -4.2 Million USD | 191.907% |
| PTC Therapeutics, Inc. | 872.33 Million USD | 99.557% |
| Mereo BioPharma Group plc | 7.42 Million USD | 48.007% |
| Cullinan Oncology, Inc. | -310 Thousand USD | 1345.484% |
| Syndax Pharmaceuticals, Inc. | -12 Thousand USD | 32275.0% |
| Absci Corporation | -41.84 Million USD | 109.226% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 77320.0% |
| 4D Molecular Therapeutics, Inc. | -76.37 Million USD | 105.055% |
| Dyne Therapeutics, Inc. | -2.46 Million USD | 256.887% |
| Kiniksa Pharmaceuticals, Ltd. | 213.73 Million USD | 98.194% |
| Ventyx Biosciences, Inc. | -941 Thousand USD | 510.308% |
| Allakos Inc. | -6.14 Million USD | 162.872% |
| Imunon, Inc. | -720 Thousand USD | 636.246% |
| Fulcrum Therapeutics, Inc. | -68.99 Million USD | 105.596% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 99.189% |
| BioAtla, Inc. | -103.73 Million USD | 103.722% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 33944.67% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 2269.101% |
| Allogene Therapeutics, Inc. | -242.81 Million USD | 101.59% |
| Larimar Therapeutics, Inc. | -311 Thousand USD | 1341.479% |
| Kezar Life Sciences, Inc. | -70.08 Million USD | 105.509% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 73.902% |
| aTyr Pharma, Inc. | -2.38 Million USD | 261.683% |
| Aligos Therapeutics, Inc. | 12.46 Million USD | 69.013% |
| Akero Therapeutics, Inc. | -29 Thousand USD | 13413.793% |
| Viridian Therapeutics, Inc. | -1 Million USD | 483.036% |
| Eliem Therapeutics, Inc. | - USD | -Infinity% |
| EyeGate Pharmaceuticals, Inc. | 13.00 USD | -29699900.0% |
| Akari Therapeutics, Plc | -4000.00 USD | 96625.0% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 99.394% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -1882.969% |
| UroGen Pharma Ltd. | 73.35 Million USD | 94.736% |
| Sutro Biopharma, Inc. | -26.69 Million USD | 114.464% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | -33155.814% |
| Orgenesis Inc. | -5.72 Million USD | 167.441% |
| Entera Bio Ltd. | -56 Thousand USD | 6994.643% |
| GH Research PLC | -315 Thousand USD | 1325.714% |
| Lisata Therapeutics, Inc. | -189 Thousand USD | 2142.857% |
| Reneo Pharmaceuticals, Inc. | -525 Thousand USD | 835.429% |
| Xencor, Inc. | -85.26 Million USD | 104.529% |
| 60 Degrees Pharmaceuticals, Inc. | -220.97 Thousand USD | 1847.241% |
| Replimune Group, Inc. | -2.65 Million USD | 245.424% |
| Coeptis Therapeutics Holdings, Inc. | -1 Million USD | 485.623% |
| Vanda Pharmaceuticals Inc. | 177.84 Million USD | 97.829% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -1882.969% |
| Portage Biotech Inc. | -54 Thousand USD | 7250.0% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 4183.338% |
| Olema Pharmaceuticals, Inc. | -377 Thousand USD | 1124.138% |
| OncoCyte Corporation | 413 Thousand USD | -834.867% |
| Qualigen Therapeutics, Inc. | -4495.00 USD | 85995.439% |
| Processa Pharmaceuticals, Inc. | -222.00 USD | 1739289.189% |
| Purple Biotech Ltd. | -196 Thousand USD | 2069.898% |
| CollPlant Biotechnologies Ltd. | 8.96 Million USD | 56.947% |
| scPharmaceuticals Inc. | 9.78 Million USD | 60.53% |
| ProMIS Neurosciences, Inc. | -10.44 Million USD | 136.965% |
| HilleVax, Inc. | -2.15 Million USD | 279.082% |
| NeuroSense Therapeutics Ltd. | -97 Thousand USD | 4080.412% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | -15 Thousand USD | 25833.138% |
| Neumora Therapeutics, Inc. Common Stock | -668 Thousand USD | 677.994% |
| Atossa Therapeutics, Inc. | -23 Thousand USD | 16886.957% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | -7506.16 USD | 51537.752% |
| Savara Inc. | -44.26 Million USD | 108.723% |
| Curis, Inc. | 9.81 Million USD | 60.646% |
| Daré Bioscience, Inc. | 2.76 Million USD | -39.41% |
| Carmell Therapeutics Corporation | -124.78 Thousand USD | 3194.048% |
| Titan Pharmaceuticals, Inc. | -1.72 Million USD | 323.308% |
| Achieve Life Sciences, Inc. | -228 Thousand USD | 1793.421% |
| BeiGene, Ltd. | 2.07 Billion USD | 99.814% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 238.095% |
| Revolution Medicines, Inc. Warrant | -399.66 Million USD | 100.966% |
| Protagonist Therapeutics, Inc. | 56.68 Million USD | 93.189% |
| Erasca, Inc. | -3.73 Million USD | 203.457% |
| bluebird bio, Inc. | -4.03 Million USD | 195.806% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 13782.756% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.797% |
| DBV Technologies S.A. | 15.72 Million USD | 75.451% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 13782.756% |
| Moderna, Inc. | 2.15 Billion USD | 99.821% |
| Vincerx Pharma, Inc. | -915 Thousand USD | 521.967% |
| Fresh Tracks Therapeutics, Inc. | 8 Million USD | 51.774% |
| Molecular Templates, Inc. | 50.39 Million USD | 92.339% |
| Acrivon Therapeutics, Inc. Common Stock | -536 Thousand USD | 820.336% |
| Travere Therapeutics, Inc. | 133.78 Million USD | 97.114% |
| Monte Rosa Therapeutics, Inc. | -6.22 Million USD | 162.054% |
| Spruce Biosciences, Inc. | -39.34 Million USD | 109.814% |
| Celldex Therapeutics, Inc. | -111.12 Million USD | 103.474% |
| Cogent Biosciences, Inc. | -3.58 Million USD | 207.609% |
| MacroGenics, Inc. | 50.52 Million USD | 92.359% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | -6.09 Million USD | 163.316% |
| Prime Medicine, Inc. | -147.9 Million USD | 102.61% |
| Aditxt, Inc. | -111.66 Thousand USD | 3557.818% |
| Adagene Inc. | 18.11 Million USD | 78.682% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 488 Thousand USD | -691.189% |
| Maravai LifeSciences Holdings, Inc. | 140.2 Million USD | 97.246% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 157.83 Million USD | 97.554% |
| SciSparc Ltd. | 2.19 Million USD | -75.82% |
| Vericel Corporation | 135.57 Million USD | 97.152% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 15513.789% |
| Minerva Neurosciences, Inc. | -30.98 Thousand USD | 12562.075% |
| Generation Bio Co. | -73.91 Million USD | 105.224% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | -437 Thousand USD | 983.524% |
| Arcutis Biotherapeutics, Inc. | 54.61 Million USD | 92.931% |
| Invivyd, Inc. | -2.02 Million USD | 290.385% |
| Relay Therapeutics, Inc. | -300.84 Million USD | 101.283% |
| Quoin Pharmaceuticals, Ltd. | -103.43 Thousand USD | 3832.671% |
| Spero Therapeutics, Inc. | 96.36 Million USD | 95.993% |
| Artelo Biosciences, Inc. | - USD | -Infinity% |
| 2seventy bio, Inc. | 98.28 Million USD | 96.072% |
| ADMA Biologics, Inc. | 88.21 Million USD | 95.623% |
| Clene Inc. | 533 Thousand USD | -624.39% |
| Capricor Therapeutics, Inc. | 24.1 Million USD | 83.985% |
| Boundless Bio, Inc. Common Stock | -957 Thousand USD | 503.448% |
| GeoVax Labs, Inc. | -20.72 Million USD | 118.633% |
| Recursion Pharmaceuticals, Inc. | 1.98 Million USD | -94.215% |
| Citius Pharmaceuticals, Inc. | -194.31 Thousand USD | 2086.97% |
| Contineum Therapeutics, Inc. Class A Common Stock | 49.8 Million USD | 92.248% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 154.442% |
| ALX Oncology Holdings Inc. | -836 Thousand USD | 561.842% |
| Vir Biotechnology, Inc. | 83.41 Million USD | 95.371% |
| Evaxion Biotech A/S | 73.11 Thousand USD | -5180.939% |
| Ocular Therapeutix, Inc. | 53.16 Million USD | 92.737% |
| Verve Therapeutics, Inc. | -173.18 Million USD | 102.229% |
| Trevena, Inc. | 1.45 Million USD | -165.361% |
| Surrozen, Inc. | -27.23 Million USD | 114.179% |
| Tyra Biosciences, Inc. | -353 Thousand USD | 1193.768% |
| Cingulate Inc. | -582.91 Thousand USD | 762.357% |
| Galmed Pharmaceuticals Ltd. | -31 Thousand USD | 12554.839% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 119.6% |
| Tenax Therapeutics, Inc. | -7570.00 USD | 51103.963% |
| Terns Pharmaceuticals, Inc. | -881 Thousand USD | 538.252% |
| ACADIA Pharmaceuticals Inc. | 680.7 Million USD | 99.433% |
| Connect Biopharma Holdings Limited | -988 Thousand USD | 490.789% |
| Clearmind Medicine Inc. | -56.34 Thousand USD | 6952.792% |
| Kronos Bio, Inc. | 1.37 Million USD | -181.414% |
| Bolt Biotherapeutics, Inc. | -53.66 Million USD | 107.194% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 1422.26% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 890.68% |
| ImmunityBio, Inc. | -17.89 Million USD | 121.582% |
| Korro Bio, Inc. | -3.63 Million USD | 206.364% |
| Kineta, Inc. | 5.43 Million USD | 28.934% |
| BioVie Inc. | -229.37 Thousand USD | 1783.255% |
| Codexis, Inc. | 57.33 Million USD | 93.266% |
| Celularity Inc. | 6.75 Million USD | 42.842% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | 3.788% |
| Celcuity Inc. | -142.77 Thousand USD | 2804.312% |
| Virax Biolabs Group Limited | 50.59 Thousand USD | -7531.943% |
| Cibus, Inc. | 1.42 Million USD | -171.519% |
| Eledon Pharmaceuticals, Inc. | -374 Thousand USD | 1132.353% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 116.846% |
| IN8bio, Inc. | -2.5 Million USD | 254.378% |
| Kodiak Sciences Inc. | -25.94 Million USD | 114.88% |
| Annexon, Inc. | -3.26 Million USD | 218.182% |
| Adverum Biotechnologies, Inc. | -2.04 Million USD | 288.894% |
| Assembly Biosciences, Inc. | -41.73 Million USD | 109.251% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -503.281% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 99.504% |
| Eyenovia, Inc. | - USD | -Infinity% |
| Puma Biotechnology, Inc. | 172.95 Million USD | 97.768% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | -1.9 Million USD | 303.211% |
| Arcellx, Inc. | 108.27 Million USD | 96.434% |
| Cardiff Oncology, Inc. | -32.36 Million USD | 111.928% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | 95.125% |
| Regulus Therapeutics Inc. | -21.15 Million USD | 118.254% |
| Moolec Science SA | -143.3 Thousand USD | 2794.254% |
| Acumen Pharmaceuticals, Inc. | -42.31 Million USD | 109.124% |
| Geron Corporation | -123.5 Million USD | 103.126% |
| LAVA Therapeutics N.V. | 3.28 Million USD | -17.463% |
| Royalty Pharma plc | 1.79 Billion USD | 99.785% |
| Atea Pharmaceuticals, Inc. | -70.09 Million USD | 105.509% |
| Greenwich LifeSciences, Inc. | -3612.00 USD | 106993.688% |
| TFF Pharmaceuticals, Inc. | 231.39 Thousand USD | -1568.604% |
| Mersana Therapeutics, Inc. | -111.41 Million USD | 103.465% |
| Humacyte, Inc. | -76.55 Million USD | 105.044% |
| Structure Therapeutics Inc. | -949.17 Thousand USD | 506.775% |
| 89bio, Inc. | -273 Thousand USD | 1514.286% |
| PMV Pharmaceuticals, Inc. | -1.25 Million USD | 407.16% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | -848 Thousand USD | 555.307% |
| Trevi Therapeutics, Inc. | -123 Thousand USD | 3239.024% |
| Lexicon Pharmaceuticals, Inc. | 1.11 Million USD | -245.04% |
| Notable Labs, Ltd. | 113 Thousand USD | -3316.814% |
| Liquidia Corporation | 14.6 Million USD | 73.555% |
| Mustang Bio, Inc. | -2.22 Million USD | 273.528% |
| Immunovant, Inc. | -231 Thousand USD | 1771.429% |
| Quantum-Si incorporated | 488 Thousand USD | -691.189% |
| Arbutus Biopharma Corporation | -55.55 Million USD | 106.949% |
| DiaMedica Therapeutics Inc. | -30 Thousand USD | 12970.0% |
| Vera Therapeutics, Inc. | 1.86 Million USD | -107.358% |
| Acasti Pharma Inc. | -11 Thousand USD | 35200.0% |
| MiNK Therapeutics, Inc. | -204.61 Thousand USD | 1986.94% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 695.416% |
| Xenon Pharmaceuticals Inc. | -167.51 Million USD | 102.305% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -240.302% |
| NeuroBo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Tempest Therapeutics, Inc. | -381 Thousand USD | 1113.386% |
| Soleno Therapeutics, Inc. | -1.95 Million USD | 297.191% |
| PepGen Inc. | -1.18 Million USD | 426.098% |
| Moleculin Biotech, Inc. | -127 Thousand USD | 3140.157% |
| United Therapeutics Corporation | 2.07 Billion USD | 99.813% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 116.862% |
| Solid Biosciences Inc. | -76.56 Million USD | 105.043% |
| BriaCell Therapeutics Corp. | -82.58 Thousand USD | 4775.296% |
| Immuneering Corporation | -764.13 Thousand USD | 605.275% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | 66.26 Thousand USD | -5726.693% |
| Belite Bio, Inc | -399 Thousand USD | 1067.669% |
| XOMA Corporation | 3.86 Million USD | 0.0% |
| ARS Pharmaceuticals, Inc. | -20.03 Million USD | 119.27% |
| Bionomics Limited | -434.44 Thousand USD | 988.712% |
| Apogee Therapeutics, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 459.497% |
| uniQure N.V. | 2.21 Million USD | -74.312% |
| Cassava Sciences, Inc. | -89.42 Million USD | 104.318% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | -92.06 Million USD | 104.194% |
| Forte Biosciences, Inc. | -9000.00 USD | 43000.0% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | -835 Thousand USD | 562.395% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| FibroBiologics, Inc. Common Stock | -437 Thousand USD | 983.524% |
| Altimmune, Inc. | -65.37 Million USD | 105.906% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 98.934% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 459.497% |
| Compugen Ltd. | 31.45 Million USD | 87.725% |
| Peak Bio, Inc. | 367.76 Thousand USD | -949.844% |
| Zevra Therapeutics, Inc. | 24.51 Million USD | 84.251% |
| Benitec Biopharma Inc. | 108 Thousand USD | -3475.0% |
| Spyre Therapeutics, Inc. | -78 Thousand USD | 5050.0% |
| NKGen Biotech, Inc. Common Stock | -1.2 Million USD | 420.948% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | -1.82 Million USD | 311.91% |
| Aileron Therapeutics, Inc. | -119 Thousand USD | 3344.538% |
| NKGen Biotech, Inc. Warrants | -1.2 Million USD | 420.948% |
| Instil Bio, Inc. | -4.75 Million USD | 181.182% |
| argenx SE | 1.1 Billion USD | 99.652% |
| Immunome, Inc. | -8.9 Million USD | 143.348% |
| Compass Therapeutics, Inc. | -1.89 Million USD | 304.286% |
| Verona Pharma plc | -679.62 Thousand USD | 668.108% |
| enGene Holdings Inc. Warrants | -175 Thousand USD | 2306.286% |
| Shattuck Labs, Inc. | -2.38 Million USD | 261.887% |
| CervoMed Inc. | -1.29 Million USD | 398.463% |
| LENZ Therapeutics, Inc. | -2.4 Million USD | 260.407% |
| Plus Therapeutics, Inc. | -4.77 Million USD | 180.825% |
| Dianthus Therapeutics, Inc. | 2.47 Million USD | -56.253% |
| Moolec Science SA | -143.3 Thousand USD | 2794.254% |
| Enveric Biosciences, Inc. | -408.03 Thousand USD | 1046.254% |
| Inovio Pharmaceuticals, Inc. | -2.67 Million USD | 244.524% |
| AnaptysBio, Inc. | 14.78 Million USD | 73.879% |
| Design Therapeutics, Inc. | -537 Thousand USD | 818.994% |
| Leap Therapeutics, Inc. | -427 Thousand USD | 1004.215% |
| NeurAxis, Inc. | 2.15 Million USD | -79.023% |
| Seelos Therapeutics, Inc. | 2.14 Million USD | -79.916% |
| Lumos Pharma, Inc. | 2 Million USD | -92.377% |
| Achilles Therapeutics plc | -4.73 Million USD | 181.606% |
| enGene Holdings Inc. Common Stock | -175 Thousand USD | 2306.286% |
| 180 Life Sciences Corp. | -105.67 Thousand USD | 3753.655% |
| Opiant Pharmaceuticals, Inc. | 31.65 Million USD | 87.804% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | -347.857% |
| ORIC Pharmaceuticals, Inc. | -1.03 Million USD | 474.128% |
| CG Oncology, Inc. Common stock | -45.54 Million USD | 108.477% |
| Fractyl Health, Inc. Common Stock | 43 Thousand USD | -8879.07% |
| Rani Therapeutics Holdings, Inc. | -822 Thousand USD | 569.708% |
| MoonLake Immunotherapeutics | -13.15 Thousand USD | 29443.365% |
| Palisade Bio, Inc. | 246 Thousand USD | -1469.512% |
| Tourmaline Bio, Inc. | -33 Thousand USD | 11800.0% |
| Beam Therapeutics Inc. | -59.67 Million USD | 106.47% |
| Neurogene Inc. | -3.26 Million USD | 218.363% |
| Mirum Pharmaceuticals, Inc. | 139.33 Million USD | 97.229% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | -3.69 Million USD | 204.577% |
| Sesen Bio, Inc. | 40 Million USD | 90.348% |
| Enliven Therapeutics, Inc. | -297 Thousand USD | 1400.0% |
| Kiora Pharmaceuticals, Inc. | -4.02 Million USD | 195.877% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 140.362% |
| Taysha Gene Therapies, Inc. | 14.08 Million USD | 72.578% |
| Athira Pharma, Inc. | -969 Thousand USD | 498.452% |
| Vaccinex, Inc. | -16 Million USD | 124.125% |
| HCW Biologics Inc. | -574.82 Thousand USD | 771.684% |
| XOMA Corporation | 3.86 Million USD | 0.0% |
| Nektar Therapeutics | 53.47 Million USD | 92.78% |
| Arvinas, Inc. | 71.8 Million USD | 94.623% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Merus N.V. | -83.46 Million USD | 104.626% |
| Omega Therapeutics, Inc. | -62.77 Million USD | 106.151% |
| Quince Therapeutics, Inc. | -322 Thousand USD | 1299.068% |
| Rezolute, Inc. | -36 Thousand USD | 10825.0% |
| Clene Inc. | 533 Thousand USD | -624.39% |
| Indaptus Therapeutics, Inc. | -1284.00 USD | 300800.935% |
| BeyondSpring Inc. | 1.75 Million USD | -120.503% |
| Synlogic, Inc. | -1.92 Million USD | 300.676% |
| Allarity Therapeutics, Inc. | -37 Thousand USD | 10535.135% |
| Phio Pharmaceuticals Corp. | -6.33 Million USD | 160.976% |
| Peak Bio, Inc. | 367.76 Thousand USD | -949.844% |
| Werewolf Therapeutics, Inc. | -18.96 Million USD | 120.361% |
| Krystal Biotech, Inc. | 47.6 Million USD | 91.89% |
| Karyopharm Therapeutics Inc. | 141.09 Million USD | 97.263% |
| SpringWorks Therapeutics, Inc. | 5.02 Million USD | 23.164% |
| Lipella Pharmaceuticals Inc. | -2.58 Million USD | 249.118% |
| MannKind Corporation | 136.19 Million USD | 97.165% |
| Ikena Oncology, Inc. | -50.49 Million USD | 107.647% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 108.81 Million USD | 96.452% |
| Gossamer Bio, Inc. | -4.38 Million USD | 188.05% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | -252 Thousand USD | 1632.143% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 77320.0% |
| Legend Biotech Corporation | 140.92 Million USD | 97.26% |
| Mural Oncology plc | -2.56 Million USD | 250.409% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 800.726% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | -100 Thousand USD | 3961.0% |
| Champions Oncology, Inc. | 20.75 Million USD | 81.396% |
| REGENXBIO Inc. | 53.02 Million USD | 92.719% |
| Ensysce Biosciences, Inc. | -5.35 Million USD | 172.075% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | -192.37 Thousand USD | 2107.018% |
| Edgewise Therapeutics, Inc. | -1.73 Million USD | 322.921% |
| Vaxart, Inc. | -60.76 Million USD | 106.354% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -262.78 Thousand USD | 1569.29% |
| Cellectis S.A. | 18 Thousand USD | -21350.0% |
| Longeveron Inc. | 221 Thousand USD | -1647.059% |
| Repare Therapeutics Inc. | -80.07 Million USD | 104.822% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 99.647% |
| Inozyme Pharma, Inc. | -1.29 Million USD | 398.377% |
| Revolution Medicines, Inc. | -399.66 Million USD | 100.966% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | -35 Thousand USD | 11131.429% |
| ArriVent BioPharma, Inc. Common Stock | - USD | -Infinity% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 49 Thousand USD | -7779.592% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.955% |
| Denali Therapeutics Inc. | -93.34 Million USD | 104.136% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 15513.789% |
| Veru Inc. | 7.56 Million USD | 48.969% |
| Corvus Pharmaceuticals, Inc. | -151 Thousand USD | 2656.954% |
| Cingulate Inc. | -582.91 Thousand USD | 762.357% |
| Passage Bio, Inc. | -3.72 Million USD | 203.762% |
| Context Therapeutics Inc. | -12.04 Thousand USD | 32157.456% |
| Exicure, Inc. | -1.42 Million USD | 371.328% |
| Day One Biopharmaceuticals, Inc. | -383 Thousand USD | 1108.094% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | -42.841% |
| Scinai Immunotherapeutics Ltd. | -512.67 Thousand USD | 853.109% |
| Rhythm Pharmaceuticals, Inc. | 68.12 Million USD | 94.333% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | -149.6 Thousand USD | 2680.762% |
| Carisma Therapeutics, Inc. | -59.2 Million USD | 106.521% |
| Unicycive Therapeutics, Inc. | 391 Thousand USD | -887.468% |
| OmniAb, Inc. | 14.66 Million USD | 73.676% |
| Anew Medical, Inc. | - USD | -Infinity% |
| Fennec Pharmaceuticals Inc. | 19.99 Million USD | 80.688% |
| Lipocine Inc. | -2.85 Million USD | 235.435% |
| Lexeo Therapeutics, Inc. Common Stock | -1.84 Million USD | 309.495% |
| Nautilus Biotechnology, Inc. | -5.7 Million USD | 167.677% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 356.325% |
| G1 Therapeutics, Inc. | 75.31 Million USD | 94.874% |
| Bellerophon Therapeutics, Inc. | -65 Thousand USD | 6040.0% |
| Sage Therapeutics, Inc. | 84.29 Million USD | 95.42% |
| Ocugen, Inc. | -33.53 Million USD | 111.513% |
| Mind Medicine (MindMed) Inc. | -3.16 Million USD | 222.106% |
| Q32 Bio Inc. | 578 Thousand USD | -567.993% |
| Brainstorm Cell Therapeutics Inc. | -265 Thousand USD | 1556.981% |
| Alumis Inc. Common Stock | -1.28 Million USD | 400.701% |
| Equillium, Inc. | 35.95 Million USD | 89.262% |
| Kyverna Therapeutics, Inc. | -1.7 Million USD | 326.186% |
| Coya Therapeutics, Inc. | 500.67 Thousand USD | -671.153% |
| CNS Pharmaceuticals, Inc. | -4134.00 USD | 93496.226% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 1590.734% |
| Evelo Biosciences, Inc. | - USD | -Infinity% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | -813.388% |
| Dominari Holdings Inc. | 2.03 Million USD | -89.358% |
| Edesa Biotech, Inc. | -183.47 Thousand USD | 2204.42% |
| vTv Therapeutics Inc. | -13.59 Million USD | 128.4% |
| Bio-Techne Corporation | 773.07 Million USD | 99.501% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 77.707% |
| Harmony Biosciences Holdings, Inc. | 460.78 Million USD | 99.162% |
| Prelude Therapeutics Incorporated | -1.16 Million USD | 430.282% |
| Candel Therapeutics, Inc. | -23.98 Million USD | 116.101% |
| iTeos Therapeutics, Inc. | 11.69 Million USD | 66.992% |
| Nkarta, Inc. | -5.86 Million USD | 165.786% |
| BioCardia, Inc. | -7.24 Million USD | 153.263% |
| Iterum Therapeutics plc | -1.75 Million USD | 320.629% |